Monday, March 18, 2019

Frelii Speaks with Potential Partners at CES about the Future of AI in DNA Sequencing and Analysis

BWW News Desk
January 11, 2019

bSPECIAL TO CESbExecutives from Frelii Inc OTCQB FRLI met with potential partners and prospects from industries including medical cannabis precision medicine consumer wellness insurance and hospital systems during the CES conference in Las Vegas Nevada The Frelii team discussed recent advancements in artificial intelligence AI systems that are fueling an AIdriven revolution in the field of genomics and DNA sequencing pblockquotep idpullquotepblockquote p The rapid evolution of AIbased DNA sequencing is delivering new insight into the genome coupled with connections and patterns of gene expression at a scale we have never seen before said Ian Jenkins CEO of Frelii Our own Frelii AI system stands at the forefront to empower personalized and precision medicine in new and exciting ways Frelii looks at every data point on the genome and analyzes how each point is interconnected with every other data point This is a fundamentally different approach to DNA sequencing and analysis We produce 60 Million data points vs the typical 400700 thousand as with typical consumer level DNA kits What we end up with are hard facts that say what the human body will do as well as information regarding what it could do when drugs medications supplements and lifestyle changes are introduced p p Companies are turning to Frelii expertise because with its AI DNA sequencing and analysis can be completed in a matter of hours as opposed to weeks or months and at a level that expands the frontiers of knowledge by analyzing massive amounts of data Most consumer DNA kits on the market look at 400000 to 700000 data points along the genome generating approximately 384 outcomes such as ancestry diet suggestions or identification of potential health risks Freliis recently improved technology has dramatically increased the data points subject to analysis to more than 60 million data points which can generate more than 60 million outcomesTo process each data point against the other data points takes billions of gigabytes of data processing for one persons physiology Freliis highefficiency Genetic Sequencing and analysis using Freliis proprietary technology has increased to greater than 99 percent and 99999 percent accuracy on whole genome and exome sequencing respectively p p This computing power enables the company to analyze more complete data The system looks at physiology and the holistic internal connections with in the human body providing insights for drug developers medical professionals and consumers p p AI combined with DNA sequencing is a match made in heaven because it can bring to light previously unexplored connections that can impact entire industries such as the rapidly expanding medical marijuana market to health care at large Jenkins said AI provides insight into the function of genetic expression and helps removes the guess work p p For example one of the ways AI and DNA sequencing can be used optimally is with medical cannabis Compared to pharmacological information there is currently very little data related medical cannabis In recent years there has been a rapid advancement in worldwide interest in medical uses of cannabis According to Viridian Capital Advisors Cannabisrelated companies raised nearly a referrerpolicyunsafeurl targetblank hrefhttpsctsbusinesswirecomctCTidsmartlinkampurlhttp3A2F2Ffortunecom2F20182F122F202Fcannabisinvestments2018ampesheet51924652ampnewsitemid20190111005301amplanenUSampanchor2413billionampindex1ampmd5feadd229168b6444e53c7902d13fe427 relnofollow13 billiona in 2018 alone Frelii is investing in its AI to empower medical professionals when seeking to provide where it is legal precision dosing of THC CBD CBN and terpenes from appropriate strains of cannabis via the right delivery format p p bAbout Frelii Incb p p Frelii Inc is a medical technology company that uses gene sequencing and artificial intelligence to determine risk and lifestyle modifications Its technology analyzes the most comprehensive markers 60000000 on the market to date Freliis technology generates accurate and profoundly valuable insight into DNA Its highefficiency Genetic Sequencing and analysis using Freliis proprietary technology has increased to greater than 99 and 99999 accuracy on bwhole genome and exome sequencingb respectively It opens opportunities never before realized in health care precision medicine insurance corporate wellness as well as personal health and risk identification For more information please visit a referrerpolicyunsafeurl targetblank hrefhttpsctsbusinesswirecomctCTidsmartlinkampurlhttp3A2F2Fwwwfreliicomampesheet51924652ampnewsitemid20190111005301amplanenUSampanchorwwwfreliicomampindex2ampmd5f8d61897c2308bc0f4041d8b75f6157e relnofollowwwwfreliicoma p p bFollow Frelii online atb p p Frelii Facebook Page a referrerpolicyunsafeurl targetblank hrefhttpsctsbusinesswirecomctCTidsmartlinkampurlhttps3A2F2Fwwwfacebookcom2Flivefrelii2Fampesheet51924652ampnewsitemid20190111005301amplanenUSampanchorhttps3A2F2Fwwwfacebookcom2Flivefrelii2Fampindex3ampmd5f95e853eb2e2f2f64997c8224942c1b8 relnofollowhttpswwwfacebookcomlivefreliiabrFrelii Twitter Feed livefreliibrFrelii Instagram Page livefreliibrFrelii LinkedIn Page linkedincomcompanyfrelii p p bSafe Harbor Statementb p p This release contains certain forwardlooking statements relating to the business of the Company All statements other than statements of historical fact included herein are forwardlooking statements including statements regarding the continued growth of the ecommerce segment and the ability of the Company to continue its expansion into that segment the ability of the Company to attract customers and partners and generate revenues the ability of the Company to successfully execute its business plan the business strategy plans and objectives of the Company and any other statements of nonhistorical information These forwardlooking statements are often identified by the use of forwardlooking terminology such as believes expects or similar expressions and involve known and unknown risks and uncertainties Although the Company believes that the expectations reflected in these forwardlooking statements are reasonable they do involve assumptions risks and uncertainties and these expectations may prove to be incorrect Investors should not place undue reliance on these forwardlooking statements which speak only as of the date of this news release The Companys actual results could differ materially from those anticipated in these forwardlooking statements as a result of a variety of factors including those discussed in the Companys periodic reports that are filed with the Securities and Exchange Commission and available on its website a referrerpolicyunsafeurl targetblank hrefhttpsctsbusinesswirecomctCTidsmartlinkampurlhttps3A2F2Fwwwglobenewswirecom2FTracker3Fdata3DKKUG77mFhVb7aadRLmItqqZYeQw5umODFLSBIKkNxCf2DKp7nTqqlDBJ02hxPl4lS37GqDiebWHaKDvDotA3D3Dampesheet51924652ampnewsitemid20190111005301amplanenUSampanchorhttp3A2F2Fwwwsecgov29ampindex4ampmd5fe849eb66dde637c17b5427ab4dc8e90 relnofollowhttpwwwsecgova All forwardlooking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors Other than as required under the securities laws the Company does not assume any duty to update these forwardlooking statements p p p

SOURCE: BUSINESS WIRE. ©2015 Business Wire


Registration Login
Registration Login
Registration Login